Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.33 |
| ▸ | PRCP | P42785 | 2/20 | 0.33 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.31 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.31 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.31 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.31 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4659265 | 1.00 | CHRNB2 (0.33) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL10067949 | 1.00 | CHRNB2 (0.33) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| Hydrochloric Acid SCHEMBL2655644 | 0.98 | CHRNB2 (0.32) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL4630213 | 0.84 | HSD17B10 (0.35) | CHRNB2CHRNA3CHRNA4PRCP | |
| SCHEMBL5597343 | 0.82 | — | — | |
| SCHEMBL4630350 | 0.81 | PRCP (0.39) | PRCP | |
| SCHEMBL28210724 | 0.81 | SLC6A1 (0.32) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL5537427 | 0.81 | SLC6A1 (0.32) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL28874795 | 0.80 | PRCP (0.41) | PRCP | |
| SCHEMBL4630457 | 0.78 | PRCP (0.44) | PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077711-A1 | Novel Ligands and Libraries of Ligands | SUNESIS PHARMACEUTICALS, INC. (US) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077711-A1 | Novel Ligands and Libraries of Ligands | LSS, ABCG2, SELL | CHRNB2 1562/4885CHRNB4 1650/4885CHRNA3 1829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.